Therapeutic blockade of activin-A improves NK cell function and antitumor immunity
Jai Rautela, Laura F Dagley, Carolina C de Oliveira, Iona S Schuster, Soroor Hediyeh-Zadeh, Rebecca B Delconte, Joseph Cursons, Robert Hennessy, Dana S Hutchinson, Craig Harrison, Badia Kita, Eric Vivier, Andrew I Webb, Mariapia A Degli-Esposti, Melissa J Davis, Nicholas D Huntington, Fernando Souza-Fonseca-Guimaraes
Science Signaling | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2019
Awarded by National Health and Medical Research Council (NHMRC) of Australia
Awarded by NHMRC
Awarded by National Breast Cancer Foundation (NBCF)
This work was supported by project grants from the National Health and Medical Research Council (NHMRC) of Australia (grants 1124784, 1066770, 1057852, and 1124907 to N.D.H.; grant 1140406 to F.S.-F.-G.; and NHMRC Program grant 1071822 to M.A.D.-E.). F.S.-F.-G. was supported by an NHMRC Early Career Fellowship (1088703), a National Breast Cancer Foundation (NBCF) Fellowship (PF-15-008), grants 1120725 and 1158085 awarded through the Priority-driven Collaborative Cancer Research Scheme, and the Cure Cancer Australia with the assistance of Cancer Australia. N.D.H. is an NHMRC CDF2 Fellow (1124788) and a recipient of a Melanoma Research Grant from the Harry J. Lloyd Charitable Trust, a Melanoma Research Alliance Young Investigator Award, a Tour De Cure research grant, an equipment grant from The Ian Potter Foundation, and a CLIP grant from Cancer Research Institute. M.A.D.-E. holds a NHMRC Principal Research Fellowship (1119298). This study was made possible through Victorian State Government Operational Infrastructure Support and the Australian Government NHMRC Independent Research Institute Infrastructure Support scheme.